Phoenix New Media Hong Kong stock | Development Pharmaceutical-B (09939) shares rebounded higher today, rising 4.74% to HK $11.96 with a turnover of HK $26.6 million.
The company previously announced that the Chinese registered phase III clinical trial of KX-826, a self-developed and potentially the world's first topical drug for the treatment of male androgenic alopecia (AGA), completed its first patient enrollment and administration on December 31, 2021. On November 24, 2021, the company announced that China's State Drug Administration (NMPA) had agreed to conduct the phase III clinical trial. Freitain is the first androgen receptor (AR) antagonist in the world to enter a registered phase III clinical trial for AGA treatment.